|
MX2015007051A
(es)
|
2012-12-07 |
2016-01-12 |
Chemocentryx Inc |
Diazol lactamas.
|
|
WO2016039749A1
(en)
|
2014-09-11 |
2016-03-17 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
EA037590B1
(ru)
|
2014-11-25 |
2021-04-19 |
Бристол-Майерс Сквибб Компани |
Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации
|
|
CA2968961A1
(en)
|
2014-11-25 |
2016-06-02 |
Bristol-Myers Squibb Company |
Methods and compositions for 18f-radiolabeling of biologics
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
ES2904252T3
(es)
|
2015-05-21 |
2022-04-04 |
Chemocentryx Inc |
Moduladores de CCR2
|
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US10358463B2
(en)
*
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
PL3439653T3
(pl)
|
2016-04-07 |
2021-07-05 |
Chemocentryx, Inc. |
Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1
|
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
|
|
HRP20210644T8
(hr)
*
|
2016-05-19 |
2021-06-25 |
Bristol-Myers Squibb Company |
Imunomodulatori za pet-snimanje
|
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
|
JP7016323B2
(ja)
|
2016-06-01 |
2022-02-21 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ－ｌ１結合ポリペプチドを用いるｐｅｔ造影
|
|
PE20191353A1
(es)
|
2016-10-14 |
2019-10-01 |
Prec Biosciences Inc |
Meganucleasas disenadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b
|
|
KR102526034B1
(ko)
*
|
2016-11-07 |
2023-04-25 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제
|
|
US10736976B2
(en)
|
2016-12-01 |
2020-08-11 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
|
|
CA3061898A1
(en)
|
2016-12-28 |
2019-10-29 |
Green Cross Lab Cell Corporation |
Chimeric antigen receptor and natural killer cells expressing same
|
|
KR102735038B1
(ko)
*
|
2017-06-23 |
2024-11-28 |
브리스톨-마이어스 스큅 컴퍼니 |
Pd-1의 길항제로서 작용하는 면역조정제
|
|
BR112020005284A2
(pt)
|
2017-09-25 |
2020-09-24 |
Chemocentryx, Inc. |
terapia de combinação usando um antagonista do receptor de quimiocina 2 (ccr2) e um inibidor de pd-1/pd-l1
|
|
EP3692053A1
(en)
|
2017-10-03 |
2020-08-12 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
US12116417B2
(en)
|
2017-11-14 |
2024-10-15 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
JP7098748B2
(ja)
|
2017-12-20 |
2022-07-11 |
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． |
Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド
|
|
AU2018392213B2
(en)
|
2017-12-20 |
2021-03-04 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
|
CA3087765A1
(en)
|
2018-01-08 |
2019-07-11 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|
|
US20190269664A1
(en)
|
2018-01-08 |
2019-09-05 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|
|
US20210040171A1
(en)
*
|
2018-02-01 |
2021-02-11 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pharmaceutical composition comprising acylated derivative of human insulin analog and preparation method thereof
|
|
US20210048439A1
(en)
*
|
2018-02-02 |
2021-02-18 |
University Of Washington |
Caged amino acids for controlled metabolic incorporation and methods of use
|
|
CN108409830B
(zh)
*
|
2018-02-05 |
2021-04-23 |
郑州大学 |
一种人pd-1蛋白胞外段亲和环肽c8及其应用
|
|
CN118084940A
(zh)
|
2018-02-13 |
2024-05-28 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
AU2019223182B2
(en)
|
2018-02-26 |
2021-08-19 |
Gilead Sciences, Inc. |
Substituted pyrrolizine compounds as HBV replication inhibitors
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
AU2019255750B2
(en)
|
2018-04-19 |
2021-10-21 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
US12331068B2
(en)
|
2018-05-31 |
2025-06-17 |
Peloton Therapeutics, Inc. |
Compositions and methods for inhibiting CD73
|
|
MX2020012939A
(es)
|
2018-05-31 |
2021-02-15 |
Ono Pharmaceutical Co |
Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios.
|
|
PE20210642A1
(es)
|
2018-07-13 |
2021-03-23 |
Gilead Sciences Inc |
Inhibidores de pd-1/pd-l1
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
TWI855000B
(zh)
|
2018-10-11 |
2024-09-11 |
日商小野藥品工業股份有限公司 |
Ｓｔｉｎｇ促效化合物
|
|
CN112955435B
(zh)
|
2018-10-24 |
2024-09-06 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
ES2979163T3
(es)
|
2018-10-31 |
2024-09-24 |
Gilead Sciences Inc |
Compuestos de 6-azabenzimidazol sustituidos como inhibidores de HPK1
|
|
TWI721624B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
|
AU2020231201B2
(en)
|
2019-03-07 |
2025-02-20 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
AU2020231115B2
(en)
|
2019-03-07 |
2025-02-20 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
KR20210146348A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
WO2020198676A1
(en)
|
2019-03-28 |
2020-10-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
JP2022533233A
(ja)
*
|
2019-05-21 |
2022-07-21 |
ブリストル－マイヤーズ スクイブ カンパニー |
免疫調整剤
|
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
|
US20220233691A1
(en)
|
2019-05-30 |
2022-07-28 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
CN114127315A
(zh)
|
2019-05-30 |
2022-03-01 |
百时美施贵宝公司 |
鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
|
|
JP2022534967A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
多腫瘍遺伝子シグネチャーおよびその使用
|
|
MX2022001434A
(es)
|
2019-08-05 |
2022-02-22 |
Ono Pharmaceutical Co |
Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios.
|
|
EP4017476A1
(en)
|
2019-08-19 |
2022-06-29 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
JP2022549273A
(ja)
|
2019-09-22 |
2022-11-24 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング
|
|
MX2022003658A
(es)
|
2019-09-30 |
2022-04-25 |
Gilead Sciences Inc |
Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.
|
|
CN115942973A
(zh)
|
2019-11-08 |
2023-04-07 |
百时美施贵宝公司 |
用于黑色素瘤的lag-3拮抗剂疗法
|
|
DK4069729T3
(da)
|
2019-12-06 |
2025-04-07 |
Prec Biosciences Inc |
Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
|
|
CN114929728A
(zh)
|
2020-01-06 |
2022-08-19 |
百时美施贵宝公司 |
免疫调节剂
|
|
EP4121442A1
(en)
*
|
2020-03-16 |
2023-01-25 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
AU2021237718B2
(en)
|
2020-03-20 |
2023-09-21 |
Gilead Sciences, Inc. |
Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
|
|
WO2021202501A1
(en)
|
2020-03-30 |
2021-10-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
EP4134134A4
(en)
|
2020-04-10 |
2023-12-27 |
ONO Pharmaceutical Co., Ltd. |
STING AGONISTIC COMPOUND
|
|
WO2021206158A1
(ja)
|
2020-04-10 |
2021-10-14 |
小野薬品工業株式会社 |
がん治療方法
|
|
CN115916340A
(zh)
*
|
2020-05-08 |
2023-04-04 |
百时美施贵宝公司 |
免疫调节剂
|
|
CN113754736A
(zh)
*
|
2020-06-02 |
2021-12-07 |
南京礼威生物医药有限公司 |
含酰肼结构的pd-l1环肽抑制剂
|
|
KR20230058442A
(ko)
|
2020-08-28 |
2023-05-03 |
브리스톨-마이어스 스큅 컴퍼니 |
간세포성 암종에 대한 lag-3 길항제 요법
|
|
BR112023003553A2
(pt)
|
2020-08-31 |
2023-04-04 |
Bristol Myers Squibb Co |
Assinatura de localização celular e imunoterapia
|
|
WO2022066635A1
(en)
|
2020-09-22 |
2022-03-31 |
Avidea Technologies, Inc. |
Compositions and methods of manufacturing amphiphilic block copolymers that form nanoparticles in situ
|
|
JP2023548051A
(ja)
|
2020-10-23 |
2023-11-15 |
ブリストル－マイヤーズ スクイブ カンパニー |
肺がんのためのｌａｇ－３アンタゴニスト療法
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
CN117157306A
(zh)
*
|
2021-03-24 |
2023-12-01 |
百时美施贵宝公司 |
免疫调节剂
|
|
AU2022246593A1
(en)
|
2021-03-29 |
2023-10-12 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
AU2022274607A1
(en)
|
2021-05-13 |
2023-11-16 |
Gilead Sciences, Inc. |
COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
|
|
EP4351657A1
(en)
|
2021-06-11 |
2024-04-17 |
Gilead Sciences, Inc. |
Combination mcl-1 inhibitors with anti-body drug conjugates
|
|
US11957693B2
(en)
|
2021-06-11 |
2024-04-16 |
Gilead Sciences, Inc. |
Combination MCL-1 inhibitors with anti-cancer agents
|
|
KR20240023628A
(ko)
|
2021-06-23 |
2024-02-22 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
US11932634B2
(en)
|
2021-06-23 |
2024-03-19 |
Gilead Sciences, Inc. |
Diacylglycerol kinase modulating compounds
|
|
CN117396478A
(zh)
|
2021-06-23 |
2024-01-12 |
吉利德科学公司 |
二酰基甘油激酶调节化合物
|
|
KR20240023629A
(ko)
|
2021-06-23 |
2024-02-22 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
CN113461519A
(zh)
*
|
2021-08-12 |
2021-10-01 |
浙江泽瑞生物医药有限公司 |
一种十八烷二酸单叔丁酯-pfp的制备方法
|
|
EP4419540A1
(en)
*
|
2021-10-20 |
2024-08-28 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
KR20240099362A
(ko)
|
2021-10-29 |
2024-06-28 |
브리스톨-마이어스 스큅 컴퍼니 |
혈액암에 대한 lag-3 길항제 요법
|
|
WO2023122945A1
(zh)
*
|
2021-12-28 |
2023-07-06 |
知和(山东)大药厂有限公司 |
环状多肽化合物及其用途
|
|
JP2025503962A
(ja)
|
2022-01-26 |
2025-02-06 |
ブリストル－マイヤーズ スクイブ カンパニー |
肝細胞がんのための併用療法
|
|
WO2023178324A1
(en)
|
2022-03-17 |
2023-09-21 |
Bristol-Myers Squibb Company |
Pharmaceutical compositions comprising salts of salcaprozate and nicotinamide for improving oral bioavailability
|
|
WO2023196964A1
(en)
|
2022-04-08 |
2023-10-12 |
Bristol-Myers Squibb Company |
Machine learning identification, classification, and quantification of tertiary lymphoid structures
|
|
WO2024013390A1
(en)
*
|
2022-07-15 |
2024-01-18 |
Universiteit Utrecht Holding B.V. |
Antiviral cyclic compounds
|
|
TW202417488A
(zh)
|
2022-08-23 |
2024-05-01 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
|
WO2024059472A1
(en)
*
|
2022-09-12 |
2024-03-21 |
Bristol-Myers Squibb Company |
Macrocyclic immunomodulators
|
|
KR20250123912A
(ko)
|
2022-12-21 |
2025-08-18 |
브리스톨-마이어스 스큅 컴퍼니 |
폐암에 대한 병용 요법
|
|
KR20250156840A
(ko)
|
2023-03-17 |
2025-11-03 |
브리스톨-마이어스 스큅 컴퍼니 |
경구 생체이용률을 개선하기 위한 약학적 조성물
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2025240243A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
US20250345390A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025245489A1
(en)
|
2024-05-24 |
2025-11-27 |
Bristol-Myers Squibb Company |
Treatment of tumors in subjects having fgl-1 positive samples
|